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Summary 
Sixteen patients with advanced squamous cell carcinoma of  the head and neck were entered into a phase II 
trial of  Aclacinomycin-A (ACM), 100 mg/M 2 administered by brief infusion every three weeks. All patients 
had received prior radiation therapy and prior non-anthracycline containing chemotherapy. No clinically 
significant disease regression was observed in fourteen patients having adequate trials. The major toxicity 
was myelosuppression; leukopenia occurred in 93~ of patients. Gastro-intestinal toxicity was mild and in- 
cluded two patients with transient liver function test abnormalities. No antitumor activity was observed in 
this patient population which was heavily pre-treated and had a median Karnofsky performance status of 
only 60%. The results of other phase II trials of ACM-A have been similarly disappointing suggesting that 
it is not a clinically useful agent in the treatment of solid tumors. 
Introduction 
Aclacinomycin-A (ACM-A) is an anthracycline 
antibiotic, prepared by aerobic fermentation of 
Streptomyces gaHlaeus. It was the first of the 
"Class I I "  anthracycline antibiotics to enter 
clinical trials functioning as a more potent inhibitor 
of  RNA synthesis than of  DNA synthesis. ACM-A 
inhibits RNA synthesis at one-tenth the concentra- 
tion at which it inhibits DNA synthesis. It may in- 
tercolate between base pairs of  DNA. Cytotoxic ef- 
fects are partially mediated through generation of  
free-radical intermediates (1, 2). It is cell cycle 
phase specific and has the maximum cytotoxicity in 
L~2ao cells at the G1-S and S-G2 boundaries. 
* Present address: Comprehensive Cancer Center, University of 
Alabama in Birmingham, University Station, Birmingham, 
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Preclinical studies in animal and human tumors 
demonstrated significant activity against L1210 and 
P388 leukemia cells, lymphosarcoma 6C3 HED cells 
(4) and human acute myelocytic leukemia (AML) 
(5). ACM-A in low dose may also act as a differen- 
tiating agent for AML cells (6). Phase I trials using 
a single dose every three weeks determined dose 
limiting toxicity to be myelosuppression with vari- 
able mild hepatic toxicity (6). Cardiac toxicity ap- 
peared similar to Adriamycin with respect to acute 
dysarrhythmic potential causing at least one case of 
complete heart block which necessitated a trans- 
venous pacemaker (3). Other toxicities were limited 
to mild nausea and vomiting and to minimal or 
non-existent alopecia. Tissue necrosis appeared to 
be much less severe than with Adriamycin (2). A 
phase II trial of  ACM-A in acute lymphocytic 
leukemia and lymphosarcoma showed significant 
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activity but none was observed in other hematol- 
ogic malignancies (7). Phase II trials in solid tumors 
have been disappointing with no significant activity 
observed against bronchogenic carcinoma (8), renal 
cell carcinoma (9), breast cancer (10) and in one 
study using a weekly 65 m g / M  2 IV dosage schedule 
in head and neck cancer (11). 
Materials and methods 
Sixteen patients with advanced histologically pro- 
ven squamous cell cancer of  the head and neck 
region, who were not better treated with surgery or 
radiation therapy were included. Prior to study en- 
try, all patients had a complete history and physical 
examination, complete blood count (CBC) with dif- 
ferential, platelet count, blood urea nitrogen, 
serum creatinine, bilirubin, SGOT, SGPT,  LDH,  
alkaline phosphatase, total serum protein and 
albumin. A chest radiograph, electrocardiogram 
and cardiac ejection fraction determination were 
obtained at the start of  therapy and repeated as 
needed during the course of  therapy. Liver-spleen 
scans, bone scans and computerized tomograms 
were obtained when clinically indicated. All pa- 
tients had an expected survival of  at least 8 weeks 
and a Karnofsky performance status of  at least 
50%. All patients had adequate bone marrow 
reserve with an initial WBC count greater that 
4000/t,1 and platelet count greater than 150,000//,1. 
Serum bilirubin was less than 2.0 mg/d l  and serum 
creatinine was less than 2.0 mg/dl .  No patient with 
a recent myocardial  infarction or congestive heart 
failure was eligible. 
ACM-A was administered as a 20 -30  minute in- 
travenous infusion at an initial dose of  100 m g / M  2 
repeated every 3 weeks. Dose adjustments were bas- 
ed on nadir counts of  the preceding cycle using the 
following criteria: 1) WBC count greater that 3000/ 
/*1 and platelet count greater than 100,000//*1, in- 
crease the dose 25%; 2) WBC count 2000-3000//.1 
and platelet count 70-100,000//*1, same dose as 
previous cycle; 3) WBC count 1000-1900//.1 or 
platelet count of  50-75,000//*1, decrease the dose 
25%; 4) WBC count less than 1000//*1 or platelets 
less than 50,000//.1, decrease the dose by 50%. Pa- 
tients were followed with weekly CBC and platelet 
counts and liver function tests. Weight, perfor- 
mance status, and tumor measurements were as- 
sessed every three weeks. Cardiotoxicity was to be 
addressed by resting and exercise MUGA scans 
before the third dose in all patients in whom a clear 
response was demonstrated. Therapy was con- 
tinued until progression of disease was document- 
ed. 
An adequate trial was defined by the completion 
of at least one full course of therapy (3 weeks) with 
response and toxicity assessment. Standard criteria 
were used to define tumor response: complete 
response (CR) - disappearance of all clinical, x- 
ray and biochemical evidence of tumor for more 
than one month; partial response (PR) - 50% or 
greater reduction in the sum of the products of  the 
greatest perpendicular diameters of  all measurable 
lesions in the absence of new disease for one month; 
minor response - between 25 and 49% reduction 
in the sum of the products of  the greatest perpen- 
dicular diameters of  all lesions; stabilization - less 
then 25 % increase in the sum of the products of  the 
greatest diameters of  all lesions; disease progression 
- more than 25% increase in the sum of the prod- 
ucts of  the greatest perpendicular diameters of  all 
lesions or the appearance of new lesions. 
Results 
Fourteen patients were evaluable for reponse. Two 
patients died from uncertain causes after the first 
course of  ACM-A before evaluation was complete. 
Table 1 shows patient characteristics. Median age 
was 57 and median performance status was 60. All 
of  the patients had been pre-treated with f rom one 
to four different chemotherapy regimens, none of 
which included Adriamycin. All had received prior 
full dose radiation therapy and all but two of the 
evaluable patients had undergone surgical resec- 
tion. Disease recurred in 64% of the patients at 
local sites or in regional neck nodes; 36% of the pa- 
tients had disease metastatic to the lung. One pa- 
tient presented as an unknown primary with mid- 
jugular neck nodes. Table 2 details the side effects. 
Dose limiting toxicity was leukopenia with 93% of  
Table l .  Patient Characteristics. 
# Evaluable patients 
Median age (range) 
Sex: Male 10 
Female 4 

















Sites of measurable disease: 
Local - regional 
Distant (lung) 
14 
57 (36 66) 
60 (50-80) 

















Table 2. Toxicity. 



































the pat ients  developing  a nad i r  W B C  count  be low 
3000/#1 and  43~ be low 2000//,1. One pat ient  re- 
qui red  hosp i ta l i za t ion  for  sepsis while leukopenic .  
Only  mi ld  anemia  (hemoglob in  d rop  o f  less than  
two grams  ~ and t h r o m b o c y t o p e n i a  were noted .  
Nausea  and vomi t ing  occur red  in 5 pat ients  and  was 
grade  3 in 2 pat ients .  Liver func t ion  tests,  S G O T  
and alkal ine  phospha ta se ,  were mi ld ly  elevated to 
less than  2 t imes no rma l  in 2 pat ients  but  resolved 
with t ime wi thout  s topp ing  therapy .  No a lopec ia  
or  ca rd io tox ic i ty  was observed.  The dose was 
escala ted in 2 pat ients .  There  were no dose a t tenua-  
t ions.  One pa t ien t  had  a s table disease course for 
two t rea tments  while all o ther  pat ients  rap id ly  pro-  
gressed.  
D i s c u s s i o n  
In this phase  I1 trial ,  no cl inical ly s ignif icant  
responses  were observed.  Al l  pat ients  were heavi ly 
p re - t rea ted  and a l though  pushed  to dose- l imi t ing  
toxici ty ,  all but  one t u m o r  rap id ly  advanced .  The 
lack o f  observab le  an t i t umor  act ivi ty  m a y  be due to 
the character is t ics  o f  the pa t ien t  popu l a t i on  entered 
into the tr ial :  med ian  p e r f o r m a n c e  status o f  60% 
and pr io r  exposure  to bo th  c h e m o t h e r a p y  and 
r ad i a t i on  the rapy  in all pat ients .  Our  results,  
however ,  conf i rm those  repor ted  by Kish et al. (11). 
W e  conclude  tha t  in this dose and schedule,  A C M -  
A is not  a useful  agent  to t rea t  advanced  squamous  
cell c a r c inoma  o f  the head  and neck.  
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